IR Biosciences Holdings Inc.
8767 East Via de Ventura
Suite 190
Scottsdale,
AZ 85258
United States - Map
Phone: 480-922-3926
Fax: 480-922-4781
Web Site: http://www.immuneregen.com
| IR BioSciences Holdings, Inc., a development-stage biotechnology company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of Homspera and its derivatives, Radilex and Viprovex. The companys product lines are designed to be used as countermeasures for homeland security threats, including radiological, chemical, and biological agents. Its Homspera is an analog of the endogenous neurokinin Substance P that is in advanced preclinical stages for immune/stem cell stimulation and wound healing. The companys Radilex is in preclinical stagesof development for use as a potential treatment for acute exposure to radiation; and Viprovex is in preclinical stages of development for the treatment of exposure to biological agents, such as infectious disease, which include influenza and anthrax. The company was founded in 1999 and is headquartered in Scottsdale, Arizona. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Michael K. Wilhelm , 41
Co-Founder, Chairman, Chief Exec. Officer, Pres, Member of Exec. Committee, Co-Founder of ImmuneRegen BioSciences Inc, Chief Exec. Officer of ImmuneRegen BioSciences Inc, Pres of ImmuneRegen BioSciences Inc of ImmuneRegen BioSciences Inc |
N/A
| N/A | Mr. John N. Fermanis , 55
Chief Financial Officer and Principal Accounting Officer |
$
137.00K | N/A | Dr. Hal N. Siegel Ph.D., 54
Chief Scientific Officer, VP, Director and Member of Scientific Advisory Board |
N/A
| N/A | Ms. Michelle R. Laroche ,
Sec. and Sec. of Immuneregen Biosciences Inc |
N/A
| N/A | Dr. K. A. Kelly McQueen MD, MPH, PLLC,
Consultant, Member of Scientific Advisory Board and Member of Bioterrorism Preparedness Advisory Board |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
